X
Xinming Jing
Researcher at Nanjing Medical University
Publications - 13
Citations - 1194
Xinming Jing is an academic researcher from Nanjing Medical University. The author has contributed to research in topics: Cancer & Cancer research. The author has an hindex of 4, co-authored 7 publications receiving 422 citations.
Papers
More filters
Journal ArticleDOI
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
TL;DR: The role of Hypoxia in cancer therapy by regulating the tumor microenvironment (TME) is summarized and the potential of hypoxia-targeted therapy is highlighted to overcome hypoxian-associated resistance in cancer treatment.
Journal ArticleDOI
Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation
Mengyan Xie,Tao Yu,Xinming Jing,Ling Ma,Yu Fan,Fengming Yang,Pei Ma,Huning Jiang,Xi Wu,Yongqian Shu,Tongpeng Xu +10 more
TL;DR: It is demonstrated that exosomal circSHKBP1 regulates the miR-582-3p/HUR/VEGF pathway, suppresses HSP90 degradation, and promotes GC progression, and is a promising circulating biomarker for GC diagnosis and prognosis and an exceptional candidate for further therapeutic exploration.
Journal ArticleDOI
The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis
TL;DR: The present meta-analysis demonstrated that miR-155 could be a potential biomarker for the detection of lung cancer but not an effective biomarkers for predicting the outcomes of Lung cancer.
Journal ArticleDOI
miR‐942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non‐small‐cell lung cancer
Fengming Yang,Chuchu Shao,Ke Wei,Xinming Jing,Zhiqiang Qin,Yuenian Shi,Yongqian Shu,Hua Shen +7 more
TL;DR: It is revealed that miR‐942 induces EMT‐related metastasis by directly targeting BARX2, which may provide a potential therapeutic strategy for NSCLC.
Journal ArticleDOI
Exosome‐transmitted miR‐769‐5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53
TL;DR: Exosomal miR‐769‐5p derived from drug‐resistant cells can be used as a potential therapeutic predictor of anti‐tumor chemotherapy to enhance the effect of anti-cancer chemotherapy, which provides a new treatment option for GC.